Where does Eikon Therapeutics, Inc. 's cash flow data come from?

Every line is extracted from Eikon Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26
Net income	-$82.96M-21.6%
Stock-based compensation	$2.78M-6.5%
Change in accounts payable	$5.32M+134%
Net cash from operating activities	-$89.8M-64.7%
Capital expenditures	$262K-98.8%
Net cash from investing activities	-$203.22M+5.0%
Proceeds from issuance of common stock	$277K+1,219%
Net cash from financing activities	$349.31M-0.3%
Interest paid	$4K-33.3%
Accretion (Amortization) of Discounts and Premiums, Investments	$827K-33.0%
Depreciation	$5.21M+37.6%
Increase Decrease In Accrued Expenses And Other Current Liabilities	-$15.07M-60.5%
Operating lease liabilities	-$2.49M-116%
Increase Decrease In Other Assets	-$2.7M-777%
Other long-term liabilities	——
Increase Decrease In Prepaid Expenses And Other Current Assets	$4.38M+63.0%
Net proceeds from sales of subsidiary shares	$349.03M—
Proceeds from issuance of redeemable convertible preferred stock	——
Accrued payables for capital expenditures	$221K-97.6%
Increase Decrease In Operating Lease Liability	-$2.49M-116%
Vesting Of Early Exercised Stock Options And Restricted Common Stock	$35K-74.5%
Cash Paid For Operating Lease Liabilities	$10.48M+310%
Free cash flow	-$90.06M-17.1%
Free cash flow	-$90.06M-17.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Eikon Therapeutics, Inc. 's cash flow data come from?: Every line is extracted from Eikon Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.